“Our team welcomes a medical technology industry expert like Hank to our board at an exciting time for our company. Interest in device therapies for hypertension is showing a real resurgence. We are completing our transvenous first-in-man study for hypertension, with clinical data expected in early 2018,” said Martin. “Hank’s experience as CEO of Boston Scientific and his broad exposure to many early-stage medical technology companies will be tremendous assets as Cibiem continues to advance its vision and pipeline of therapies.”
Kucheman brings a breadth of experience to Cibiem. He currently serves as a director of BioStar Ventures III, a U.S. medical device venture capital fund, and serves as a board director for several medical technology companies in both the public and private sectors. Prior to joining BioStar, Kucheman served as CEO of Boston Scientific Corp., before which he served as executive vice president and president of the Cardiology, Rhythm and Vascular (CRV) Group at the company.
“I’m excited to join Cibiem’s Board of Directors and work with the team to bring this important therapy to patients,” said Kucheman. “Cibiem’s combination of clinical data, a unique IP position and the diagnostic capability to identify patients most likely to respond to treatment all make for an opportunity that will provide a huge benefit for patients.”
Kucheman is joining the Cibiem Board of Directors in conjunction with an early investment by BioStar Ventures, ahead of a company-planned Series C financing slated for the first quarter of 2018. Additionally, Dr. Louis Cannon (founding partner of BioStar) is joining the Cibiem Scientific Advisory Board.
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based transvenous approach focused on carotid body modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. Cibiem is developing a method to pre-screen patients likely to respond to therapy which will allow physicians to better provide care to patients with targeted therapy. The Los Altos, Calif.-based company was co-founded by Mark Gelfand and Levin, M.D., the team of entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures, SV Health Investors and BioStar Ventures.